Which has better earnings & valuation, BWAY or TMDX?

TransMedics Group has higher revenue and earnings than Brainsway. TransMedics Group is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainsway $52.22M 10.84 $7.57M $0.35 40.29 TransMedics Group $605.49M 4.32 $190.29M $4.40 17.21

Does the media favor BWAY or TMDX?

In the previous week, TransMedics Group had 3 more articles in the media than Brainsway. MarketBeat recorded 6 mentions for TransMedics Group and 3 mentions for Brainsway. Brainsway's average media sentiment score of 0.91 beat TransMedics Group's score of 0.65 indicating that Brainsway is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainsway 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, AXGN or BWAY?

Brainsway has lower revenue, but higher earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 9.32 -$15.70M -$0.64 N/A Brainsway $52.22M 10.84 $7.57M $0.35 40.29

Is AXGN or BWAY more profitable?

Brainsway has a net margin of 15.68% compared to AxoGen's net margin of -13.21%. Brainsway's return on equity of 12.28% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.21% -9.63% -6.26% Brainsway 15.68% 12.28% 7.75%

Does the media favor AXGN or BWAY?

In the previous week, AxoGen had 1 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for AxoGen and 3 mentions for Brainsway. AxoGen's average media sentiment score of 1.08 beat Brainsway's score of 0.91 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Brainsway 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, LMAT or BWAY?

LeMaitre Vascular has higher revenue and earnings than Brainsway. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LeMaitre Vascular $249.60M 9.18 $57.73M $2.71 37.01 Brainsway $52.22M 10.84 $7.57M $0.35 40.29

Does the media favor LMAT or BWAY?

In the previous week, LeMaitre Vascular had 2 more articles in the media than Brainsway. MarketBeat recorded 5 mentions for LeMaitre Vascular and 3 mentions for Brainsway. Brainsway's average media sentiment score of 0.91 beat LeMaitre Vascular's score of 0.41 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Brainsway 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BFLY or BWAY?

In the previous week, Butterfly Network had 7 more articles in the media than Brainsway. MarketBeat recorded 10 mentions for Butterfly Network and 3 mentions for Brainsway. Brainsway's average media sentiment score of 0.91 beat Butterfly Network's score of -0.12 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Butterfly Network 2 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Brainsway 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, NVCR or BWAY?

Brainsway has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 2.84 -$136.23M -$1.53 N/A Brainsway $52.22M 10.84 $7.57M $0.35 40.29

Is NVCR or BWAY more profitable?

Brainsway has a net margin of 15.68% compared to NovoCure's net margin of -25.66%. Brainsway's return on equity of 12.28% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -25.66% -50.82% -16.48% Brainsway 15.68% 12.28% 7.75%

Does the media prefer NVCR or BWAY?

In the previous week, NovoCure had 5 more articles in the media than Brainsway. MarketBeat recorded 8 mentions for NovoCure and 3 mentions for Brainsway. Brainsway's average media sentiment score of 0.91 beat NovoCure's score of 0.51 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Brainsway 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Brainsway (BWAY) Competitors

$14.10 -0.96 (-6.37%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$14.38 +0.28 (+1.99%)

As of 09:09 AM Eastern

Compare

BWAY vs. TMDX, AXGN, LMAT, BFLY, and NVCR

Should you buy Brainsway stock or one of its competitors? MarketBeat compares Brainsway with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Brainsway include TransMedics Group (TMDX), AxoGen (AXGN), LeMaitre Vascular (LMAT), Butterfly Network (BFLY), and NovoCure (NVCR). These companies are all part of the "medical equipment" industry.

How does Brainsway compare to TransMedics Group?

Brainsway (NASDAQ:BWAY) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Brainsway presently has a consensus target price of $16.00, suggesting a potential upside of 13.48%. TransMedics Group has a consensus target price of $134.50, suggesting a potential upside of 77.58%. Given TransMedics Group's higher probable upside, analysts plainly believe TransMedics Group is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

TransMedics Group has higher revenue and earnings than Brainsway. TransMedics Group is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.22M	10.84	$7.57M	$0.35	40.29
TransMedics Group	$605.49M	4.32	$190.29M	$4.40	17.21

In the previous week, TransMedics Group had 3 more articles in the media than Brainsway. MarketBeat recorded 6 mentions for TransMedics Group and 3 mentions for Brainsway. Brainsway's average media sentiment score of 0.91 beat TransMedics Group's score of 0.65 indicating that Brainsway is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainsway	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Brainsway has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market.

30.1% of Brainsway shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 19.0% of Brainsway shares are owned by company insiders. Comparatively, 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TransMedics Group has a net margin of 27.04% compared to Brainsway's net margin of 15.68%. TransMedics Group's return on equity of 22.38% beat Brainsway's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.68%	12.28%	7.75%
TransMedics Group	27.04%	22.38%	8.46%

Summary

TransMedics Group beats Brainsway on 11 of the 16 factors compared between the two stocks.

How does Brainsway compare to AxoGen?

AxoGen (NASDAQ:AXGN) and Brainsway (NASDAQ:BWAY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

AxoGen has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

80.3% of AxoGen shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 2.4% of AxoGen shares are held by insiders. Comparatively, 19.0% of Brainsway shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, AxoGen had 1 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for AxoGen and 3 mentions for Brainsway. AxoGen's average media sentiment score of 1.08 beat Brainsway's score of 0.91 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainsway	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Brainsway has a net margin of 15.68% compared to AxoGen's net margin of -13.21%. Brainsway's return on equity of 12.28% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
Brainsway	15.68%	12.28%	7.75%

AxoGen currently has a consensus price target of $46.50, suggesting a potential upside of 17.75%. Brainsway has a consensus price target of $16.00, suggesting a potential upside of 13.48%. Given AxoGen's higher possible upside, equities analysts plainly believe AxoGen is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Brainsway has lower revenue, but higher earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	9.32	-$15.70M	-$0.64	N/A
Brainsway	$52.22M	10.84	$7.57M	$0.35	40.29

Summary

Brainsway beats AxoGen on 10 of the 16 factors compared between the two stocks.

How does Brainsway compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and Brainsway (NASDAQ:BWAY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

LeMaitre Vascular has a net margin of 24.35% compared to Brainsway's net margin of 15.68%. LeMaitre Vascular's return on equity of 15.36% beat Brainsway's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
Brainsway	15.68%	12.28%	7.75%

LeMaitre Vascular presently has a consensus target price of $112.60, suggesting a potential upside of 12.27%. Brainsway has a consensus target price of $16.00, suggesting a potential upside of 13.48%. Given Brainsway's stronger consensus rating and higher possible upside, analysts clearly believe Brainsway is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by company insiders. Comparatively, 19.0% of Brainsway shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

LeMaitre Vascular has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Brainsway has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

LeMaitre Vascular has higher revenue and earnings than Brainsway. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	9.18	$57.73M	$2.71	37.01
Brainsway	$52.22M	10.84	$7.57M	$0.35	40.29

In the previous week, LeMaitre Vascular had 2 more articles in the media than Brainsway. MarketBeat recorded 5 mentions for LeMaitre Vascular and 3 mentions for Brainsway. Brainsway's average media sentiment score of 0.91 beat LeMaitre Vascular's score of 0.41 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brainsway	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LeMaitre Vascular beats Brainsway on 9 of the 16 factors compared between the two stocks.

How does Brainsway compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and Brainsway (NASDAQ:BWAY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Brainsway has lower revenue, but higher earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	21.09	-$77.06M	-$0.30	N/A
Brainsway	$52.22M	10.84	$7.57M	$0.35	40.29

Butterfly Network presently has a consensus price target of $5.56, suggesting a potential downside of 31.20%. Brainsway has a consensus price target of $16.00, suggesting a potential upside of 13.48%. Given Brainsway's stronger consensus rating and higher probable upside, analysts clearly believe Brainsway is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Butterfly Network had 7 more articles in the media than Brainsway. MarketBeat recorded 10 mentions for Butterfly Network and 3 mentions for Brainsway. Brainsway's average media sentiment score of 0.91 beat Butterfly Network's score of -0.12 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	2 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brainsway	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Butterfly Network has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

Brainsway has a net margin of 15.68% compared to Butterfly Network's net margin of -73.63%. Brainsway's return on equity of 12.28% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-73.63%	-34.41%	-23.91%
Brainsway	15.68%	12.28%	7.75%

37.9% of Butterfly Network shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 22.0% of Butterfly Network shares are held by insiders. Comparatively, 19.0% of Brainsway shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Brainsway beats Butterfly Network on 9 of the 15 factors compared between the two stocks.

How does Brainsway compare to NovoCure?

NovoCure (NASDAQ:NVCR) and Brainsway (NASDAQ:BWAY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Brainsway has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.84	-$136.23M	-$1.53	N/A
Brainsway	$52.22M	10.84	$7.57M	$0.35	40.29

In the previous week, NovoCure had 5 more articles in the media than Brainsway. MarketBeat recorded 8 mentions for NovoCure and 3 mentions for Brainsway. Brainsway's average media sentiment score of 0.91 beat NovoCure's score of 0.51 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainsway	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.6% of NovoCure shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 5.5% of NovoCure shares are held by company insiders. Comparatively, 19.0% of Brainsway shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

NovoCure has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Brainsway has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

Brainsway has a net margin of 15.68% compared to NovoCure's net margin of -25.66%. Brainsway's return on equity of 12.28% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
Brainsway	15.68%	12.28%	7.75%

NovoCure currently has a consensus target price of $23.60, suggesting a potential upside of 46.67%. Brainsway has a consensus target price of $16.00, suggesting a potential upside of 13.48%. Given NovoCure's higher probable upside, equities research analysts plainly believe NovoCure is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Brainsway beats NovoCure on 12 of the 16 factors compared between the two stocks.

Get Brainsway News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BWAY vs. The Competition

Export

Metric	Brainsway	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$604.35M	$8.82B	$7.05B	$12.61B
Dividend Yield	N/A	2.54%	2.68%	8.00%
P/E Ratio	40.29	16.09	27.10	24.26
Price / Sales	10.84	7.04	588.85	117.88
Price / Cash	64.32	18.40	29.22	49.36
Price / Book	7.54	3.57	10.85	6.29
Net Income	$7.57M	$228.19M	$3.58B	$330.66M
7 Day Performance	-5.87%	-2.31%	-2.12%	-1.35%
1 Month Performance	-3.62%	-0.62%	3.27%	-0.64%
1 Year Performance	130.58%	-2.73%	26.33%	19.08%

Brainsway Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BWAY Brainsway	3.0109 of 5 stars	$14.10 -6.4%	$16.00 +13.5%	+129.1%	$604.35M	$52.22M	40.29	120	News Coverage Gap Down
TMDX TransMedics Group	4.3628 of 5 stars	$70.54 -1.0%	$134.50 +90.7%	-32.7%	$2.43B	$605.49M	16.00	210
AXGN AxoGen	2.9801 of 5 stars	$45.44 -1.2%	$46.50 +2.3%	+232.1%	$2.41B	$225.21M	N/A	450	Positive News
LMAT LeMaitre Vascular	3.9633 of 5 stars	$104.64 +0.9%	$112.60 +7.6%	+19.8%	$2.39B	$249.60M	38.66	490
BFLY Butterfly Network	1.0296 of 5 stars	$7.87 -4.4%	$5.56 -29.3%	+346.7%	$2.01B	$97.61M	N/A	460

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BWAY) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Brainsway (BWAY) Competitors

BWAY vs. TMDX, AXGN, LMAT, BFLY, and NVCR

How does Brainsway compare to TransMedics Group?

Summary

How does Brainsway compare to AxoGen?

Summary

How does Brainsway compare to LeMaitre Vascular?

Summary

How does Brainsway compare to Butterfly Network?

Summary

How does Brainsway compare to NovoCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BWAY vs. The Competition

Brainsway Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Brainsway (BWAY) Competitors

BWAY vs. TMDX, AXGN, LMAT, BFLY, and NVCR

How does Brainsway compare to TransMedics Group?

Do analysts rate BWAY or TMDX?

Which has better earnings & valuation, BWAY or TMDX?

Does the media favor BWAY or TMDX?

Which has more risk and volatility, BWAY or TMDX?

Do insiders and institutionals hold more shares of BWAY or TMDX?

Is BWAY or TMDX more profitable?

Summary

How does Brainsway compare to AxoGen?

Which has more volatility & risk, AXGN or BWAY?

Do insiders & institutionals hold more shares of AXGN or BWAY?

Does the media favor AXGN or BWAY?

Is AXGN or BWAY more profitable?

Do analysts recommend AXGN or BWAY?

Which has better valuation and earnings, AXGN or BWAY?

Summary

How does Brainsway compare to LeMaitre Vascular?

Is LMAT or BWAY more profitable?

Do analysts recommend LMAT or BWAY?

Do institutionals and insiders hold more shares of LMAT or BWAY?

Which has more volatility and risk, LMAT or BWAY?

Which has higher earnings & valuation, LMAT or BWAY?

Does the media favor LMAT or BWAY?

Summary

How does Brainsway compare to Butterfly Network?

Which has higher valuation and earnings, BFLY or BWAY?

Do analysts rate BFLY or BWAY?

Does the media prefer BFLY or BWAY?

Which has more risk and volatility, BFLY or BWAY?

Is BFLY or BWAY more profitable?

Do institutionals & insiders have more ownership in BFLY or BWAY?

Summary

How does Brainsway compare to NovoCure?

Which has stronger earnings & valuation, NVCR or BWAY?

Does the media prefer NVCR or BWAY?

Do institutionals and insiders have more ownership in NVCR or BWAY?

Which has more risk & volatility, NVCR or BWAY?

Is NVCR or BWAY more profitable?

Do analysts rate NVCR or BWAY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BWAY vs. The Competition

Brainsway Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools